GlassScriptPhysician profile
Hafez Hayek
NPI 1053584888
$137,523.30
in general payments reported to CMS, 2019-2025
37 companies · $14K in 2025
The $14K reported for 2025 was more than what 96% of Critical Care Medicine (Internal Medicine) providers received nationally (typical 2025 total: $189).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,445 · 2020: $32K · 2021: $26K · 2022: $24K · 2023: $28K · 2024: $12K · 2025: $14K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $39K · Travel and Lodging: $6,940 · Education: $4,545 · Food and Beverage: $4,067.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $38,900.00 |
| Travel and Lodging | $6,940.01 |
| Education | $4,545.04 |
| Food and Beverage | $4,066.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $101,772.35 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals LP | $21,327.01 | 2019-2025 | Airsupra, Tezspire, Breztri |
| Intuitive Surgical, INC. | $6,607.87 | 2025 | |
| Medical Device Business Services, INC. | $2,372.28 | 2022-2024 | Monarch |
| Ethicon INC. | $1,597.62 | 2019-2025 | Monarch Platform |
| Boehringer Ingelheim Pharmaceuticals, INC. | $706.78 | 2019-2025 | Ofev, Stiolto Respimat, Jascayd |
| Genzyme Corporation | $420.37 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $371.73 | 2022-2025 | Dupixent |
| Insmed, INC. | $272.55 | 2019-2025 | Arikayce |
| Mylan Specialty L.P. | $186.14 | 2019-2024 | Yupelri |
| Verona Pharma, INC. | $181.63 | 2025 | Ohtuvayre |
| Philips North America LLC | $180.98 | 2019-2022 | |
| Foundation Medicine, INC. | $165.02 | 2021 | |
| Lilly USA, LLC | $153.78 | 2025 | Zepbound |
| Olympus America INC. | $126.75 | 2025 |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hafez Hayek listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.